Search Results

Containing any of the words

Only of the type

"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlledClinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729)in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" Drug Clinical Trial

"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" Drug Clinical Trial

A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed' Drug Clinical Trial

A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed' Drug Clinical Trial

CEO of SFDA Discusses “Regulatory Pathways: Balancing Innovation and Safety” at the Global Healthspan Summit 2025 News

SFDA Chief Executive Officer Launches the 2nd. Saudi Conference for Drug Registration and Legislations News

Recall all batches of HANDY SPRAY -ISOPROPYL ALCOHOL 70% Drugs Circulars and withdrawal

Recall All batches of MOXICLAV 1 gm Film Coted Tablet Drugs Circulars and withdrawal

A SR 40 Million project to launch a lab for Fruit, Veggies and Canned Food in Jeddah Municipality News

The Saudi FDA Joins Global Regulators at 27th International Medical Device Regulators Forum (IMDRF) in Tokyo News